Komal Jhaveri, MD, FACP, and Paolo Tarantino, MD, discuss updates in the treatment of metastatic breast cancer (mBC) from SABCS 2022 and other recent meetings, and how to best incorporate recent data into clinical practice.
January 30th 2023
Paolo Tarantino, MD, provides an overview of ER-positive, HER2-negative metastatic breast cancer (ER+/HER2- mBC), highlighting the prevalence, patient populations, and the typical prognosis.
Komal Jhaveri, MD, FACP, explains data on the frontline standard of care treatment approaches for ER-positive HER2-negative mBC.
February 7th 2023
Dr Komal Jhaveri highlights important data on oral SERDs for ER-positive HER2-negative mBC that was presented at recent meetings.
February 13th 2023
Komal Jhaveri, MD, FACP, discusses the role of capivasertib in ER-positive HER2-negative mBC and the design and outcomes of the CAPItello 291 trial.
February 22nd 2023
Drs Jhaveri and Tarantino discuss the standard of practice for managing triple negative breast cancer.
Dr Jhaveri explains her thoughts on sequencing ADCs in the treatment of triple-negative breast cancer.
March 2nd 2023
Komal Jhaveri, MD, FACP, explains the potential role ADCs may have in the future of breast cancer treatment.
Paolo Tarantino, MD, highlights additional abstracts from SABCS 2022 that he found particularly interesting.